Recent announcements
POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands
Enables the efficient expansion of surface targets for radioisotope delivery
POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
Enrollment in PNT2002's SPLASH trial is complete and topline data is expected in the fourth quarter of 2023. Next-generation actinium-225 PSMA program PNT2001 phase 1 trial design released; first patient dosed expected in Q1 2024. Company released its first terbium-161 preclinical data, and announced additional isotope supply partnerships for actinium-225 and lead-212.
ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177
The expanded agreement broadens the supply of ITM’s non-carrier-added lutetium-177 (n.c.a. 177Lu) to POINT to enable its usage in the clinical and potential future commercial development of the 177Lu-based molecules in POINT’s development pipeline.
POINT Biopharma Expands Its Research with Next-Generation Isotopes, Publishing New Preclinical Data at SNMMI’s Annual Congress
Auger electron and beta emitting isotope terbium-161 was paired with POINT’s FAP-targeted PNT6555 ligand and showed robust anti-tumor efficacy, similar to actinium-225 and lutetium-177 labeled PNT6555. Preclinical proof-of-concept established for synergistic interaction of immuno- and radioligand therapies with lutetium-177 labeled PNT6555.
POINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands
POINT’s vertically integrated platform together with AdvanCell’s lead-212 (212Pb) generator technology enables both the development and scaled commercialization of 212Pb-labeled radioligand therapies.
POINT Biopharma Announces Appointment of Dr. Bridget Martell to its Board of Directors
Announced the filling of its vacant board seat with the appointment of Bridget Martell, M.A., M.D. to its Board of Directors.
POINT Biopharma to Host Virtual Investor Day on Tuesday, June 20, 2023
Register online today at https://hub.pointbiopharma.com/investor-day-june-2023
POINT Biopharma Announces FRONTIER Trial-in-Progress Poster Presentation at ASCO
PNT2004 program’s phase 1 FRONTIER trial design to be presented. Abstract to be released at 5:00 PM ET, May 25th. Poster to be available starting at 9:00 AM ET, June 3rd.